Eisai Sets FY2028 Revenue Goal of ¥1 Trillion ($6.7B) on Oncology, Dementia Growth

Why It Matters

Eisai’s trillion‑yen revenue target signals a decisive pivot toward high‑value specialty drugs, a strategy that could reshape Japan’s pharmaceutical export profile. Success would validate the commercial viability of Alzheimer’s disease treatments, a segment that has historically struggled with market acceptance. Moreover, the forecast puts pressure on rivals to accelerate their own specialty pipelines, potentially intensifying R&D spending across the sector. The projection also has macro‑economic implications: a stronger Eisai could boost Japan’s trade balance in pharmaceuticals and attract foreign investment into the country’s biotech ecosystem. Conversely, missing the target could dampen investor confidence in Japanese pharma’s ability to compete globally, especially as Western firms continue to dominate the dementia and oncology markets.

Key Takeaways

• Eisai projects FY2028 revenue of ¥1 trillion ($6.7 bn), a 30%+ increase from FY2025.
• Leqembi expected to generate ¥300 billion ($2.0 bn) in FY2028, up from ¥88 billion ($590 m) in FY2025.
• Dayvigo forecast to reach ¥100 billion ($670 m) in FY2028, up from ¥64.3 billion ($430 m) in FY2025.
• Core operating profit target set at ¥90 billion ($600 m) for FY2028.
• Guidance hinges on continued U.S. reimbursement approval and market uptake of Leqembi and Dayvigo.

Pulse Analysis

Eisai’s FY2028 outlook reflects a broader industry transition from volume‑driven generic sales to high‑margin biologics and targeted therapies. The company’s confidence in Leqembi suggests that the Alzheimer’s market, long plagued by failed trials, may finally be reaching a commercial tipping point. If Leqembi can sustain its projected growth, it could set a pricing precedent that encourages other firms to invest in amyloid‑targeting candidates, potentially revitalizing a stagnant therapeutic area.

From a competitive standpoint, Eisai’s aggressive revenue target puts it in direct contention with global giants like Biogen, Eli Lilly and Roche, all of which have robust dementia and oncology pipelines. Eisai’s advantage lies in its early partnership model and its ability to leverage Japan’s strong regulatory pathways to accelerate approvals. However, the company must navigate pricing scrutiny, especially in the U.S., where payer resistance could erode the projected ¥300 billion Leqembi revenue.

Looking ahead, the FY2028 guidance will serve as a barometer for investor sentiment toward Japanese pharma’s capacity to innovate at scale. A successful hit could trigger a wave of capital inflows into Japan’s biotech sector, spurring collaborations and M&A activity. Conversely, any shortfall may reinforce the narrative that Japanese firms are lagging behind Western counterparts in specialty drug commercialization. Stakeholders should monitor quarterly updates, regulatory decisions, and competitive launches to gauge whether Eisai’s trillion‑yen ambition is realistic or overly optimistic.